Premium
Gastrin‐releasing peptide is a potent vasodilator in humans
Author(s) -
Clive Sally,
Jodrell Duncan,
Webb David
Publication year - 2001
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1067/mcp.2001.114888
Subject(s) - tachyphylaxis , vasodilation , gastrin releasing peptide , medicine , nitric oxide , brachial artery , calcitonin gene related peptide , forearm , endocrinology , gastrin , pharmacology , neuropeptide , bombesin , blood pressure , receptor , surgery , secretion
Objectives Our objective was to characterize the local vascular effects of gastrin‐releasing peptide in forearm resistance vessels as a biomarker to aid the clinical development of broad‐spectrum neuropeptide antagonists as anticancer agents. Methods On different occasions, 7 healthy male volunteers received brachial artery infusions of gastrin‐releasing peptide, and forearm blood flow was measured by venous occlusion plethysmography. Dose‐finding studies identified a range of pharmacologically active doses of gastrin‐releasing peptide (3 to 450 pmol/min) for use in dose response and tachyphylaxis studies. The nitric oxide clamp method was used for the assessment of the contribution of nitric oxide to the vasodilatory effect shown. Results and Conclusions Gastrin‐releasing peptide proved to be a potent, dose‐dependent arteriolar vasodilator. The time to onset and offset of effect was rapid, within minutes, and marked tachyphylaxis was shown, with recovery by approximately 20 minutes. The contribution of nitric oxide to this vasodilatation was minimal. Forearm blood flow studies with the use of gastrin‐releasing peptide may be usefully incorporated into the further clinical development of broad‐spectrum neuropeptide growth factor antagonists. Clinical Pharmacology & Therapeutics (2001) 69 , 252–259; doi: 10.1067/mcp.2001.114888